CTOs on the Move

Actavis

www.actavis.com

 
Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.actavis.com
  • 400 Interpace Pkwy
    Parsippany, NY USA 07054
  • Phone: 862.261.7000

Executives

Name Title Contact Details

Similar Companies

Sleep Prescription

Sleep Prescription is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals, headquartered at Pune in West India, is an Indian pharmaceutical company.

Auxillium East

Auxillium East is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Afecta Pharmaceuticals

Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.